文献速递生殖医学妇科

妇科内镜手术中经阴道获取未成熟卵母细胞行体外成熟以拓展生育力保存范围

Enhancing the scope of in vitro maturation for fertility preservation: transvaginal retrieval of immature oocytes during endoscopic gynaecological procedures.
PubMed 文献 · Hum Reprod · 2020-01-01

这项前瞻性队列研究纳入158例因其他原因行腹腔镜或宫腔镜的无排卵多囊卵巢综合征(PCOS)女性,在术中经阴道获取未成熟卵母细胞并行体外成熟(IVM-surgery)。每启动IVM周期临床妊娠率9.5%(15/158)、活产率6.9%(11/158),未见不良新生儿结局,术后无并发症且卵巢功能未受损。作者认为该策略可作为需妇科手术女性的生育力保存新选择,但需更多研究筛选适宜人群并评估成本效益。

要点

  • 妇科内镜术中经阴道取卵行IVM对无刺激卵巢是可行的生育力保存新选择。
  • 每启动IVM周期临床妊娠率9.5%、活产率6.9%,未见不良新生儿结局。
  • 术后无并发症、住院时间未延长、卵巢功能未受损,但样本小需谨慎解读。

核心结论

  • IVM-surgery对无刺激卵巢是可供需妇科手术女性考虑的生育力保存新选择,但需更多研究确定适宜获益人群及成本效益。

研究设计与样本

  • 前瞻性队列研究,纳入2014至2016年在本不孕中心因其他原因行腹腔镜或宫腔镜并同期经阴道取卵行IVM的158例连续无排卵PCOS女性。
  • 新鲜卵母细胞组46例,卵母细胞冷冻组112例,其中33例后续解冻行授精与卵裂期胚胎移植。

主要发现

  • 全部IVM-surgery女性每启动IVM周期临床妊娠率为9.5%(15/158),活产率为6.9%(11/158)。
  • 冻融卵母细胞组40.6%(20/33)的女性获得高质量卵裂胚胎,卵母细胞存活率83.0%。
  • 新鲜卵母细胞组每移植周期临床妊娠率69.2%、活产率53.8%;冷冻卵母细胞组分别为28.6%和19.1%。
  • 未记录到不良新生儿结局,IVM-surgery与术后并发症、住院时间延长或卵巢功能受损无关。

临床怎么用

  • 对需行妇科内镜手术且有生育力保存需求的女性,可考虑同期经阴道获取未成熟卵母细胞行IVM并冻存卵母细胞或胚胎。
  • 该策略也可帮助排卵正常患者获得可用卵母细胞与胚胎用于冻存及后续使用。

局限性

  • 样本量小,且每次取卵的利用率与成本效益低,结果需谨慎解读。
  • 需进一步研究对活产儿进行长期随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Could in vitro maturation (IVM) following transvaginal oocyte retrieval during gynaecological surgery (IVM-surgery) be an effective and safe strategy for fertility preservation? SUMMARY ANSWER: IVM-surgery on unstimulated ovaries is a novel option that can be considered for fertility preservation for women requiring gynaecological surgery, but more research is needed to identify appropriate patients who may benefit and to determine the cost-effectiveness of such an approach. WHAT IS KNOWN ALREADY: IVM followed by oocyte/embryo cryopreservation has been useful as a safe reproductive strategy for some infertile women. STUDY DESIGN, SIZE, DURATION: This prospective cohort study comprised 158 consecutive women with polycystic ovary syndrome (PCOS) who underwent laparoscopy or hysteroscopy for other reasons and had concomitant transvaginal oocyte retrieval followed by IVM between 2014 and 2016. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 158 women with anovulatory PCOS who underwent IVM-surgery in our infertility centre were recruited for this study. Matured IVM oocytes obtained from these women were either freshly fertilized and subsequently frozen at the blastocyst stage (fresh oocyte group, n = 46) or the oocytes were frozen (frozen oocyte group, n = 112) for fertility preservation followed by later thawing for insemination and cleavage embryo transfer (ET) (n = 33). The following outcomes were then evaluated: embryological data, clinical pregnancy rate, live birth rate (LBR), neonatal outcomes, post-operative complications and post-operative ovarian function. MAIN RESULTS AND THE ROLE OF CHANCE: Among all the women who underwent IVM-surgery, the clinical pregnancy rate and LBR per initiated IVM cycle were 9.5% (15/158) and 6.9% (11/158), respectively. Women (40.6%, 20/33) who underwent the procedure with frozen-thawed oocytes (oocyte survival rate, 83.0%) obtained a high quality of cleaved embryos. In the fresh oocyte group, the clinical pregnancy rate and LBR per ET cycle were 69.2 and 53.8%, respectively. In the frozen oocyte group, the clinical pregnancy rate and LBR per ET cycle were 28.6 and 19.1%, respectively. No adverse neonatal outcomes were recorded. IVM-surgery was not associated with post-operative complications, a longer hospital stay, or impaired ovarian function. LIMITATIONS, REASONS FOR CAUTION: Because of the small sample size and the low utilization rate and cost-effectiveness per retrieval, the present findings should be interpreted with caution, and further studies are needed for the long-term follow-up of live births. WIDER IMPLICATIONS OF THE FINDINGS: This strategy can also help patients with normal ovulation to obtain available oocytes and embryos for cryopreservation and subsequent use. STUDY FUNDING/COMPETING INTEREST(S): This research was supported by the Joint Research Fund for Overseas Natural Science of China (No. 31429004), the National Key Research and Development Program of China (No. 2017YFC1002000, 2017YFC1001504, 2016YFC1000302), the Ministry of Science and Technology of China Grants (No. 2014CB943203), the Chinese Society of Reproductive Medicine Fund (No. 16020400656) and the National Natural Science Foundation of China (No. 81300456). All the authors have nothing to disclose in terms of conflicts of interest. TRIAL REGISTRATION NUMBER: chictr-ONC-17011861.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Song XL, Lu CL, Zheng XY, et al. Enhancing the scope of in vitro maturation for fertility preservation: transvaginal retrieval of immature oocytes during endoscopic gynaecological procedures. Hum Reprod. 2020. PMID: 32154563. doi:10.1093/humrep/dez273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。